590 completed, 143 unknown, 62 terminated, 53 recruiting. 259 Phase 4, 215 Phase 3, 200 Phase 2, 149 Phase 1, 105 Not applicable.
Follow Atorvastatin: new trials by email Literature Review of Atorvastatin trials Research Report on Atorvastatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque Alirocumab, Placebo, Atorvastatin - Carotid Stenosis | Phase 3 | Not yet recruiting | Middle East North Africa Stroke and Interventional Neurotherapies Organization | 280 | 2027-07-01 | 2026-05-14 |
| RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque Remodeling Intervention 1, Intervention 3, Intervention 2 - Atherosclerosis Cerebral, Carotid Plaque | Phase 4 | Not yet recruiting | Keqiang Zhao | 120 | 2027-01-01 | 2026-09-15 |
| Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium - Cerebral Infarction | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran) - Melanoma | Not applicable | Recruiting | University of Colorado, Denver | 40 | 2026-10-19 | 2026-10-22 |
| Comparing Inclisiran Versus Statin for Primary Aldosteronism inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug) - Primary Aldosteronism | Not applicable | Recruiting | Third Military Medical University | 50 | 2026-10-01 | 2026-10-21 |
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia | Phase 3 | Not yet recruiting | Daiichi Sankyo | 103 | 2026-09-30 | 2026-09-29 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
| Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome Inclisiran, Atorvastatin or Rosuvastatin, Ezetimibe - Acute Coronary Syndromes (ACS) | Phase 4 | Not yet recruiting | Seoul National University Bundang Hospital | 294 | 2026-09-01 | 2026-09-02 |
| A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers Atorvastatin Calcium, Telmisartan - Drug-drug Interactions | Phase 1 | Not yet recruiting | Huons Co., Ltd. | 28 | 2026-09-01 | 2026-09-10 |
| Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 1 | Not yet recruiting | Banu Aji Dibyasakti | 64 | 2026-08-30 | 2026-08-13 |
| Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease Atorvastatin and Lisinopril, Placebo - Chest Wall Tumor, Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 60 | 2026-08-12 | 2026-09-17 |
| Perioperative Statins to Prevent AFib After Lung Surgery Atorvastatin, Matching Placebo - Postoperative Atrial Fibrillation, Lung Surgery | Phase 4 | Recruiting | Peking Union Medical College Hospital | 540 | 2026-08-01 | 2026-07-28 |
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants HRS-1301 Tablets, Atorvastatin Calcium Tablets, Midazolam oral solution - Hyperlipidemias | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 16 | 2026-06-08 | 2026-09-30 |
| Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Pitavastatin/ezetimibe, Atorvastatin or Rosuvastatin - Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Not applicable | Not yet recruiting | Samsung Medical Center | 5000 | 2026-06-01 | 2026-06-10 |
| Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP atorvastatin, NAC, and romiplostim - Immune Thrombocytopenic Purpura | Not applicable | Not yet recruiting | Peking University People's Hospital | 50 | 2026-06-01 | 2026-06-23 |
| Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity UBT251, Metformin hydrochloride, Warfarin Sodium - Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics | Phase 1 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 48 | 2026-05-27 | 2026-08-25 |
| PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC Axitinib, Toripalimab, Atorvastatin - Advanced Renal Cell Carcinoma (RCC), PTC | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2026-05-14 | 2026-06-05 |
| Statins Against Bushfire Smoke Atorvastatin, Placebo - Healthy Adults | Phase 4 | Not yet recruiting | Menzies Institute for Medical Research | 100 | 2026-05-01 | 2026-03-10 |
Showing 20 of 926. Sign in to see all of them.
Hypercholesterolemia (134) · Dyslipidemias (85) · Hyperlipidemias (75) · Coronary Artery Disease (55) · Cardiovascular Diseases (50) · Atherosclerosis (44) · Diabetes Mellitus, Type 2 (34) · Diabetes Mellitus (33) · Hypertension (32) · Acute Coronary Syndrome (28) · Stroke (27) · Inflammation (26) · Coronary Disease (23) · Myocardial Infarction (19) · Breast Neoplasms (17)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (32) · Organon and Co (31) · Pfizer (24) · AstraZeneca (23) · Yonsei University (14) · Eli Lilly and Company (13) · Sanofi (12) · Chong Kun Dang Pharmaceutical (11) · Merck Sharp & Dohme LLC (9) · GlaxoSmithKline (8) · Samsung Medical Center (8) · Abbott (7) · Boryung Pharmaceutical Co., Ltd (7) · Takeda (7) · Tanta University (7)
United States (257) · China (106) · South Korea (82) · Canada (61) · United Kingdom (43) · Italy (42) · Denmark (34) · Netherlands (34) · Germany (33) · Egypt (30) · France (26) · Australia (24) · Russia (24) · Spain (24) · Poland (23)
Russell Esterline (7) · Erling B. Pedersen, Professor (4) · Anna Toso, MD (3) · Bolanle A Omotoso, MD (3) · Adam T Hill, MBChB MD (2) · Amira B Kassem, PhD (2)
PMID 38018702, PMID 30183102, PMID 21518985, PMID 19029469, PMID 20167359, PMID 27513651, PMID 27777279, PMID 28573499, PMID 31020900, PMID 34298554, PMID 16731270, PMID 17407645, PMID 18783301, PMID 19116237, PMID 20110022, PMID 20130232, PMID 20228610, PMID 20432394, PMID 20531008, PMID 20645885, PMID 20681275, PMID 20934572, PMID 21067804, PMID 21613319, PMID 22019563, PMID 22576673, PMID 23183941, PMID 23303884, PMID 23674398, PMID 24216317, PMID 25060413, PMID 25431239, PMID 25660356, PMID 26872608, PMID 27480425, PMID 27847338, PMID 28214794, PMID 28964736, PMID 30571333, PMID 31867054, PMID 32791950, PMID 34515113, PMID 36413436, PMID 37462232, PMID 37565307, PMID 10190267, PMID 10634801, PMID 10650325, PMID 10859281, PMID 10919968
2005 (4), 2016 (3), 2017 (3), 2019 (3), 2004 (2), 2008 (2), 2009 (2), 2015 (2), 2023 (2), 2025 (2), P30CA015704 (2), R01AR071263 (2), R01HL106041 (2), 2014 (1), 2018 (1)